DIG
ZURA icon

Dauntless Investment Group’s Zura Bio ZURA Stock Holding History

Dauntless Investment Group’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-61,010
Closed -$320K – 94
2025
Q4 		$320K Buy
+61,010
New +$241K 0.25% 43

Other funds holding ZURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Dauntless Investment Group's ZURA Position: Q1 2026 in Review

Dauntless Investment Group sold out of Zura Bio (ZURA) in Q1 2026, closing a stake of 61,010 shares — an estimated $320K sold.

Dauntless Investment Group first reported a position in ZURA in Q4 2025 and held it in 1 quarter. The position peaked at $320K in Q4 2025. 94 funds tracked by Wall St. Rank hold ZURA as of Q1 2026.

  • Dauntless Investment Group reported no remaining Zura Bio position as of Q1 2026 after selling out during the quarter.
  • Dauntless Investment Group sold 61,010 Zura Bio shares in Q1 2026, an estimated $320K.
  • Dauntless Investment Group first reported a position in Zura Bio in Q4 2025 and held it in 1 quarter.
  • Dauntless Investment Group's Zura Bio position peaked at $320K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Zura Bio as of Q1 2026.

Based on Dauntless Investment Group's 13F filing for Q1 2026, filed 14 May 2026.